Central precocious puberty (CPP) results from premature reactivation of the hypothalamic-pituitary-gonadal axis and is increasingly recognized as a systemic condition linked to cardiometabolic health. Genetic mutations, particularly in imprinted genes such as MKRN3 and DLK1, are major monogenic causes of familial CPP, while rare activating variants in KISS1 and KISS1R highlight the pivotal role of kisspeptin signaling. Neuropeptides, including kisspeptin and neurokinin B, are central to pubertal regulation. Advances in clinical assessment, biochemical markers, pelvic ultrasound, and genetic testing have improved diagnostic precision, though differentiating CPP from benign variants remains challenging. Gonadotropin-releasing hormone analogs remain the gold standard for halting progression and optimizing adult height, while novel neuropeptide modulators show promise. Beyond growth outcomes, accumulating evidence indicates significant cardiometabolic sequelae, underscoring the importance of early, precision-guided intervention. Integrating genomic, neuropeptidergic, and metabolic insights can refine diagnosis, guide therapy, and potentially mitigate lifelong cardiovascular risk in affected females.
{"title":"Genetic, neuropeptidergic, and cardiometabolic interplay in female central precocious puberty.","authors":"Aygun Khaleddin Musayeva, Mahira Firudinkizi Amirova","doi":"10.1097/XCE.0000000000000343","DOIUrl":"10.1097/XCE.0000000000000343","url":null,"abstract":"<p><p>Central precocious puberty (CPP) results from premature reactivation of the hypothalamic-pituitary-gonadal axis and is increasingly recognized as a systemic condition linked to cardiometabolic health. Genetic mutations, particularly in imprinted genes such as <i>MKRN3</i> and <i>DLK1</i>, are major monogenic causes of familial CPP, while rare activating variants in <i>KISS1</i> and <i>KISS1R</i> highlight the pivotal role of kisspeptin signaling. Neuropeptides, including kisspeptin and neurokinin B, are central to pubertal regulation. Advances in clinical assessment, biochemical markers, pelvic ultrasound, and genetic testing have improved diagnostic precision, though differentiating CPP from benign variants remains challenging. Gonadotropin-releasing hormone analogs remain the gold standard for halting progression and optimizing adult height, while novel neuropeptide modulators show promise. Beyond growth outcomes, accumulating evidence indicates significant cardiometabolic sequelae, underscoring the importance of early, precision-guided intervention. Integrating genomic, neuropeptidergic, and metabolic insights can refine diagnosis, guide therapy, and potentially mitigate lifelong cardiovascular risk in affected females.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 3","pages":"e00343"},"PeriodicalIF":1.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The effects of dairy products on type 2 diabetes mellitus (T2DM) are unclear. Some studies have revealed the beneficial effects, whereas others found harmful effects of dairy products on the risk of T2DM. The objective of the present study was to investigate the association of different types of dairy products with risk of T2DM in Iranian adults.
Methods: This cross-sectional study included a total of 4241 individuals. Among these participants, 1804 were diagnosed with T2DM or prediabetes, whereas the remaining 2437 individuals were without T2DM. A validated food frequency questionnaire was used to assess the consumption of different types of dairy products.
Results: A positive association was found between T2DM with dietary intake of milk [odds ratio (OR): 1.16, 95% confidence interval (CI): 1.11-1.23, P = 0.008] and cheese (OR: 1.90, 95% CI: 1.41-2.29, P = 0.001) after adjustment for age, sex, physical activity, BMI, education level, energy, and fat intake. There was no significant association between T2DM and dietary intake of total dairy, yogurt, ayran (yogurt drink), and curd.
Conclusion: A positive association was found between the consumption of some dairy products including milk and cheese and the risk of T2DM. Further longitudinal studies are warranted to approve this finding.
背景:乳制品对2型糖尿病(T2DM)的影响尚不清楚。一些研究揭示了乳制品的有益影响,而另一些研究则发现乳制品对患2型糖尿病的风险有有害影响。本研究的目的是调查不同类型的乳制品与伊朗成年人患2型糖尿病风险的关系。方法:本横断面研究共纳入4241人。在这些参与者中,1804人被诊断为T2DM或糖尿病前期,而其余2437人没有T2DM。一份经过验证的食物频率问卷用于评估不同类型乳制品的消费情况。结果:在调整年龄、性别、体力活动、BMI、教育水平、能量和脂肪摄入后,T2DM与牛奶(比值比(OR): 1.16, 95%可信区间(CI): 1.11-1.23, P = 0.008)和奶酪(OR: 1.90, 95% CI: 1.41-2.29, P = 0.001)的饮食摄入呈正相关。T2DM与总乳制品、酸奶、ayran(酸奶饮料)和凝乳摄入量之间没有显著关联。结论:食用牛奶和奶酪等乳制品与患2型糖尿病的风险呈正相关。进一步的纵向研究证实了这一发现。
{"title":"The association between consumption of dairy products and risk of type 2 diabetes.","authors":"Soroor Fathi, Mahsa Vahdat, Zahra Saeedirad, Naeemeh Hassanpour Ardekanizadeh, Mahdi Mousavi Mele, Soheila Shekari, Khadijeh Abbasi Mobarakeh, Hanieh Shafaei, Alireza Mosavi Jarrahi, Asma Rajabi Harsini, Sara Khoshdooz, Maryam Gholamalizadeh, Hamideh YazdiMoghaddam, Saeid Doaei","doi":"10.1097/XCE.0000000000000318","DOIUrl":"10.1097/XCE.0000000000000318","url":null,"abstract":"<p><strong>Background: </strong>The effects of dairy products on type 2 diabetes mellitus (T2DM) are unclear. Some studies have revealed the beneficial effects, whereas others found harmful effects of dairy products on the risk of T2DM. The objective of the present study was to investigate the association of different types of dairy products with risk of T2DM in Iranian adults.</p><p><strong>Methods: </strong>This cross-sectional study included a total of 4241 individuals. Among these participants, 1804 were diagnosed with T2DM or prediabetes, whereas the remaining 2437 individuals were without T2DM. A validated food frequency questionnaire was used to assess the consumption of different types of dairy products.</p><p><strong>Results: </strong>A positive association was found between T2DM with dietary intake of milk [odds ratio (OR): 1.16, 95% confidence interval (CI): 1.11-1.23, <i>P</i> = 0.008] and cheese (OR: 1.90, 95% CI: 1.41-2.29, <i>P</i> = 0.001) after adjustment for age, sex, physical activity, BMI, education level, energy, and fat intake. There was no significant association between T2DM and dietary intake of total dairy, yogurt, ayran (yogurt drink), and curd.</p><p><strong>Conclusion: </strong>A positive association was found between the consumption of some dairy products including milk and cheese and the risk of T2DM. Further longitudinal studies are warranted to approve this finding.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"14 1","pages":"e00318"},"PeriodicalIF":1.3,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Hypertension is the most prominent and well acknowledged chronic disease in developed countries and is a significant contributor to global mortality. The present study aimed to investigate the association between hypertension and different types of dietary carbohydrates.
Method: This cross-sectional study was conducted on 4184 people aged 35-70, including 1239 patients with hypertension and 2945 subjects with normal blood pressure (BP) in Sabzevar, Iran. The dietary intake data were collected through the administration of a semiquantitative Food Frequency Questionnaire. Utilizing Nutritionist IV software, dietary glucose, fructose, simple sugar, carbohydrate, and galactose consumption were evaluated.
Results: A direct association was found between dietary glucose and BP (odds ratio: 1.02; 95% CI: 1.01-1.05; P = 0.04). This association remained significant after adjusting for age. Further adjustments for education, marital status, job, physical activity, and BMI, and additional adjustments for energy intake did not change the results.
Conclusion: In summary, the present study identified a significant association between hypertension and dietary intake of glucose. Considering that carbohydrates are an essential part of the diet worldwide, these findings can be valuable in formulating dietary interventions for hypertensive patients.
{"title":"The association between hypertension and different types of dietary carbohydrates.","authors":"Alireza Rafieipour, Mobina Zeinalabedini, Soheila Shekari, Fatemeh Azaryan, Zahra Salimi, Naeemeh Hassanpour Ardekanizadeh, Zahra Mahmoudi, Atefeh Kohansal, Ali Shamsi-Goushki, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Sara Khoshdooz, Saeid Doaei, Akram Kooshki","doi":"10.1097/XCE.0000000000000317","DOIUrl":"10.1097/XCE.0000000000000317","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is the most prominent and well acknowledged chronic disease in developed countries and is a significant contributor to global mortality. The present study aimed to investigate the association between hypertension and different types of dietary carbohydrates.</p><p><strong>Method: </strong>This cross-sectional study was conducted on 4184 people aged 35-70, including 1239 patients with hypertension and 2945 subjects with normal blood pressure (BP) in Sabzevar, Iran. The dietary intake data were collected through the administration of a semiquantitative Food Frequency Questionnaire. Utilizing Nutritionist IV software, dietary glucose, fructose, simple sugar, carbohydrate, and galactose consumption were evaluated.</p><p><strong>Results: </strong>A direct association was found between dietary glucose and BP (odds ratio: 1.02; 95% CI: 1.01-1.05; <i>P</i> = 0.04). This association remained significant after adjusting for age. Further adjustments for education, marital status, job, physical activity, and BMI, and additional adjustments for energy intake did not change the results.</p><p><strong>Conclusion: </strong>In summary, the present study identified a significant association between hypertension and dietary intake of glucose. Considering that carbohydrates are an essential part of the diet worldwide, these findings can be valuable in formulating dietary interventions for hypertensive patients.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"13 4","pages":"e00317"},"PeriodicalIF":1.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14eCollection Date: 2024-12-01DOI: 10.1097/XCE.0000000000000316
Sasan Rahmanian, Zahra Salimi, Mohammad Masoumvand, Zohre Aghakhani Nejad, Mohamadtaghi Ghorbani Hesari, Seyed Reza Mirshafaei, Mohammad Keshavarz Mohammadian, Khadijeh Abbasi Mobarakeh, Masoomeh Ataei Kachooei, Ali Shamsi-Goushki, Sara Khoshdooz, Parsa Bahmani, Saeid Doaei, Akram Kooshki, Maryam Gholamalizadeh
Background: Hypertension (HTN) is a major global public health issue influenced by genetics and lifestyle factors such as diet and psychological stress. Previous research suggests a potential link between HTN and dietary vitamin A intake. This study aims to explore the association between HTN and the intake of various forms of vitamin A.
Methods: This cross-sectional study was conducted on 1239 patients with HTN and 2945 normotensive individuals aged 35-70 years in Sabzevar, Iran. Dietary vitamin A intake was assessed using the Nutritionist IV software and a food frequency questionnaire.
Result: A positive association was found between HTN with total vitamin A intake [odds ratio (OR): 1.03, 95% confidence interval (CI): 1.01-1.05, P = 0.04] and β-carotene intake (OR: 1.03, 95% CI: 1.02-1.05, P = 0.03) after adjusting for age and sex. These associations remained statistically significant after adjusting for physical activity and BMI. The association between HTN and β-carotene intake remained significant after additional adjustment for calorie intake. No significant association was observed between dietary retinol intake and HTN.
Conclusion: Increased dietary intake of vitamin A and β-carotene may be associated with a higher risk of HTN. Further longitudinal studies are needed to confirm these findings and elucidate the underlying mechanisms.
背景:高血压(HTN)是一个主要的全球公共卫生问题,受遗传和生活方式因素(如饮食和心理压力)的影响。先前的研究表明,HTN与饮食中维生素a的摄入量之间存在潜在的联系。本研究旨在探讨HTN与各种维生素a摄入之间的关系。方法:本横断面研究在伊朗Sabzevar进行,年龄在35-70岁之间的1239例HTN患者和2945例血压正常的个体。使用营养师IV软件和食物频率问卷评估膳食维生素A摄入量。结果:调整年龄和性别后,HTN与总维生素A摄入量[比值比(OR): 1.03, 95%可信区间(CI): 1.01-1.05, P = 0.04]和β-胡萝卜素摄入量(OR: 1.03, 95% CI: 1.02-1.05, P = 0.03)呈正相关。在调整体力活动和体重指数后,这些关联仍然具有统计学意义。在额外调整卡路里摄入量后,HTN与β-胡萝卜素摄入量之间的关联仍然显著。饮食中视黄醇摄入量与HTN之间无显著相关性。结论:饮食中维生素A和β-胡萝卜素摄入量的增加可能与HTN的高风险有关。需要进一步的纵向研究来证实这些发现并阐明潜在的机制。
{"title":"Does dietary intake of vitamin A and beta-carotene increase the risk of hypertension?","authors":"Sasan Rahmanian, Zahra Salimi, Mohammad Masoumvand, Zohre Aghakhani Nejad, Mohamadtaghi Ghorbani Hesari, Seyed Reza Mirshafaei, Mohammad Keshavarz Mohammadian, Khadijeh Abbasi Mobarakeh, Masoomeh Ataei Kachooei, Ali Shamsi-Goushki, Sara Khoshdooz, Parsa Bahmani, Saeid Doaei, Akram Kooshki, Maryam Gholamalizadeh","doi":"10.1097/XCE.0000000000000316","DOIUrl":"10.1097/XCE.0000000000000316","url":null,"abstract":"<p><strong>Background: </strong>Hypertension (HTN) is a major global public health issue influenced by genetics and lifestyle factors such as diet and psychological stress. Previous research suggests a potential link between HTN and dietary vitamin A intake. This study aims to explore the association between HTN and the intake of various forms of vitamin A.</p><p><strong>Methods: </strong>This cross-sectional study was conducted on 1239 patients with HTN and 2945 normotensive individuals aged 35-70 years in Sabzevar, Iran. Dietary vitamin A intake was assessed using the Nutritionist IV software and a food frequency questionnaire.</p><p><strong>Result: </strong>A positive association was found between HTN with total vitamin A intake [odds ratio (OR): 1.03, 95% confidence interval (CI): 1.01-1.05, <i>P</i> = 0.04] and β-carotene intake (OR: 1.03, 95% CI: 1.02-1.05, <i>P</i> = 0.03) after adjusting for age and sex. These associations remained statistically significant after adjusting for physical activity and BMI. The association between HTN and β-carotene intake remained significant after additional adjustment for calorie intake. No significant association was observed between dietary retinol intake and HTN.</p><p><strong>Conclusion: </strong>Increased dietary intake of vitamin A and β-carotene may be associated with a higher risk of HTN. Further longitudinal studies are needed to confirm these findings and elucidate the underlying mechanisms.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"13 4","pages":"e00316"},"PeriodicalIF":1.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-28eCollection Date: 2023-12-01DOI: 10.1097/XCE.0000000000000293
Adrian H Heald, John Warner-Levy, Lleyton Belston, Hellena Habete-Asres, Linda Horne, Ann Metters, Martin Whyte, Martin Gibson
{"title":"Success story of GLP-1 agonist (Liraglutide) treatment in someone with type 1 diabetes: a life transformed.","authors":"Adrian H Heald, John Warner-Levy, Lleyton Belston, Hellena Habete-Asres, Linda Horne, Ann Metters, Martin Whyte, Martin Gibson","doi":"10.1097/XCE.0000000000000293","DOIUrl":"10.1097/XCE.0000000000000293","url":null,"abstract":"","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 4","pages":"e293"},"PeriodicalIF":1.3,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-18eCollection Date: 2023-12-01DOI: 10.1097/XCE.0000000000000290
Shahab Fatemi, Stefan Acosta, Moncef Zarrouk, Peter M Nilsson, Anders Gottsäter
Objectives: Patients with type 2 diabetes mellitus (DM) run lower risk for abdominal aortic aneurysm (AAA, aortic diameter ≥ 30 mm) and its complications. We aimed to evaluate associations between disturbances in glucose metabolism and arterial stiffness, AAA, and abdominal aortic diameter in 65-year-old men.
Methods: Forty-eight 65-year-old men with screening-detected AAA and 115 men with normal abdominal aortic diameter underwent examination of glucose metabolism and arterial stiffness.
Results: Men with AAA had higher BMI, waist-hip ratio (WHR), frequency of DM, haemoglobin A1c, smoking exposure, and plasma insulin levels at 0, 60 and 120 min during OGTT compared to those without. The increase in p-insulin (P < 0.001) after OGTT was also higher in men with AAA, adjusted for smoking, WHR, and nadir value of p-insulin. In analyses adjusted for smoking, use of lipid-lowering agents, and WHR, the increase in p-insulin at 2-hours (P = 0.006) after OGTT and p-homocysteine were associated with abdominal aortic diameter. There were no differences between groups in aortic stiffness or skin autofluorescence Advanced Glycation End products.
Conclusion: In this population-based study hyperinsulinaemia as a marker of insulin resistance, but not hyperglycaemia or aortic stiffness, was associated with AAA and abdominal aortic diameter in 65-year-old men.
目的:2型糖尿病(DM)患者发生腹主动脉瘤(AAA,主动脉直径≥30)的风险较低 mm)及其并发症。我们旨在评估65岁男性的葡萄糖代谢紊乱与动脉硬化、AAA和腹主动脉直径之间的关系。方法:48名65岁男性筛查出AAA,115名腹主动脉直径正常的男性接受糖代谢和动脉硬化检查。结果:AAA男性在0、60和120时具有较高的BMI、腰臀比、糖尿病发生率、血红蛋白A1c、吸烟暴露和血浆胰岛素水平 分钟。对胰岛素增加(p P = 0.006)和p-同型半胱氨酸与腹主动脉直径相关。两组之间在主动脉硬化或皮肤自发荧光晚期糖化终产物方面没有差异。结论:在这项基于人群的研究中,高胰岛素血症作为胰岛素抵抗的标志,而不是高血糖或主动脉硬化,与65岁男性的AAA和腹主动脉直径有关。
{"title":"A population-based study on hyperinsulinaemia and arterial stiffness in men with and without abdominal aortic aneurysm.","authors":"Shahab Fatemi, Stefan Acosta, Moncef Zarrouk, Peter M Nilsson, Anders Gottsäter","doi":"10.1097/XCE.0000000000000290","DOIUrl":"10.1097/XCE.0000000000000290","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with type 2 diabetes mellitus (DM) run lower risk for abdominal aortic aneurysm (AAA, aortic diameter ≥ 30 mm) and its complications. We aimed to evaluate associations between disturbances in glucose metabolism and arterial stiffness, AAA, and abdominal aortic diameter in 65-year-old men.</p><p><strong>Methods: </strong>Forty-eight 65-year-old men with screening-detected AAA and 115 men with normal abdominal aortic diameter underwent examination of glucose metabolism and arterial stiffness.</p><p><strong>Results: </strong>Men with AAA had higher BMI, waist-hip ratio (WHR), frequency of DM, haemoglobin A<sub>1c</sub>, smoking exposure, and plasma insulin levels at 0, 60 and 120 min during OGTT compared to those without. The increase in p-insulin (<i>P</i> < 0.001) after OGTT was also higher in men with AAA, adjusted for smoking, WHR, and nadir value of p-insulin. In analyses adjusted for smoking, use of lipid-lowering agents, and WHR, the increase in p-insulin at 2-hours (<i>P</i> = 0.006) after OGTT and p-homocysteine were associated with abdominal aortic diameter. There were no differences between groups in aortic stiffness or skin autofluorescence Advanced Glycation End products.</p><p><strong>Conclusion: </strong>In this population-based study hyperinsulinaemia as a marker of insulin resistance, but not hyperglycaemia or aortic stiffness, was associated with AAA and abdominal aortic diameter in 65-year-old men.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 4","pages":"e0290"},"PeriodicalIF":1.3,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/XCE.0000000000000291
Małgorzata Niemiec, Nicola Dyrek, Klaudia Żądecka, Bartosz Gruchlik, Adrianna Berger-Kucza, Katarzyna Mizia-Stec
We present an unusual clinical case of a 39-year-old woman admitted to the Department of Cardiology due to stenocardial pain accompanied by hypertensive crisis. The patient presented with severe chest pain and high blood pressure, along with a history of type 2 diabetes, hyperlipidemia, smoking, and hypertension. Initial tests showed elevated troponin T, glucose, CRP, and D-dimer levels, and electrocardiography and transthoracic echocardiography showed abnormalities suggesting acute myocardial infarction, but angiography did not reveal any significant coronary artery blockages. Further tests and imaging led to a diagnosis of takotsubo syndrome (TTS) and suspicion of pheochromocytoma, which was confirmed later biopsy. The presented case is very rare because the coexistence of TTS and pheochromocytoma is not common due to the rarity of the tumor. It is very important to make a quick and accurate diagnosis, because improperly treated cases can lead to death.
{"title":"Takotsubo syndrome with several hypertensive crises: an unexpected diagnosis.","authors":"Małgorzata Niemiec, Nicola Dyrek, Klaudia Żądecka, Bartosz Gruchlik, Adrianna Berger-Kucza, Katarzyna Mizia-Stec","doi":"10.1097/XCE.0000000000000291","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000291","url":null,"abstract":"<p><p>We present an unusual clinical case of a 39-year-old woman admitted to the Department of Cardiology due to stenocardial pain accompanied by hypertensive crisis. The patient presented with severe chest pain and high blood pressure, along with a history of type 2 diabetes, hyperlipidemia, smoking, and hypertension. Initial tests showed elevated troponin T, glucose, CRP, and D-dimer levels, and electrocardiography and transthoracic echocardiography showed abnormalities suggesting acute myocardial infarction, but angiography did not reveal any significant coronary artery blockages. Further tests and imaging led to a diagnosis of takotsubo syndrome (TTS) and suspicion of pheochromocytoma, which was confirmed later biopsy. The presented case is very rare because the coexistence of TTS and pheochromocytoma is not common due to the rarity of the tumor. It is very important to make a quick and accurate diagnosis, because improperly treated cases can lead to death.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 3","pages":"e0291"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10225339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/XCE.0000000000000286
Adrian H Heald, Mike Stedman, Chris Daly, John Julian Warner-Levy, Mark Livingston, Lamiece Hussain, Simon Anderson
Early weight gain following initiation of antipsychotic treatment predicts longer-term weight gain, with attendant long-term consequences including premature cardiovascular events/death. An important question is whether there is a difference in weight change over time between people with affective versus nonaffective psychosis. Here we describe the results of a real-world analysis of the BMI change in the months postdiagnosis with affective versus nonaffective psychosis.
Methods: We undertook an anonymised search across one Primary Care Network in Cheshire, UK with a total population of 32 301 individuals. We reviewed the health records of anyone who had been diagnosed over a 10-year period between June 2012 and June 2022 for the first time with first episode nonaffective psychosis versus psychosis associated with depression or bipolar affective disorder (affective psychosis).
Results: The overall % change in BMI was +8% in nonaffective psychosis individuals and +4% in those with a diagnosis of affective psychosis - however, the distribution was markedly skewed for nonaffective psychosis patients. Using caseness as >30% increase in BMI; affective = 4% cases and nonaffective = 13% cases, there was a three-fold difference in terms of increase in BMI. In regression analysis, the r2 linking the initial BMI to % change in BMI was 0.13 for nonaffective psychosis and 0.14 for affective psychosis.
Conclusion: The differences observed here in the distribution of weight change over time between individuals with affective versus nonaffective psychosis may relate to underlying constitutional differences. The phenotypic and genetic factors underlying this difference remain to be defined.
{"title":"First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis.","authors":"Adrian H Heald, Mike Stedman, Chris Daly, John Julian Warner-Levy, Mark Livingston, Lamiece Hussain, Simon Anderson","doi":"10.1097/XCE.0000000000000286","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000286","url":null,"abstract":"<p><p>Early weight gain following initiation of antipsychotic treatment predicts longer-term weight gain, with attendant long-term consequences including premature cardiovascular events/death. An important question is whether there is a difference in weight change over time between people with affective versus nonaffective psychosis. Here we describe the results of a real-world analysis of the BMI change in the months postdiagnosis with affective versus nonaffective psychosis.</p><p><strong>Methods: </strong>We undertook an anonymised search across one Primary Care Network in Cheshire, UK with a total population of 32 301 individuals. We reviewed the health records of anyone who had been diagnosed over a 10-year period between June 2012 and June 2022 for the first time with first episode nonaffective psychosis versus psychosis associated with depression or bipolar affective disorder (affective psychosis).</p><p><strong>Results: </strong>The overall % change in BMI was +8% in nonaffective psychosis individuals and +4% in those with a diagnosis of affective psychosis - however, the distribution was markedly skewed for nonaffective psychosis patients. Using caseness as >30% increase in BMI; affective = 4% cases and nonaffective = 13% cases, there was a three-fold difference in terms of increase in BMI. In regression analysis, the <i>r</i><sup>2</sup> linking the initial BMI to % change in BMI was 0.13 for nonaffective psychosis and 0.14 for affective psychosis.</p><p><strong>Conclusion: </strong>The differences observed here in the distribution of weight change over time between individuals with affective versus nonaffective psychosis may relate to underlying constitutional differences. The phenotypic and genetic factors underlying this difference remain to be defined.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 3","pages":"e0286"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/73/xce-12-e0286.PMC10289689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/XCE.0000000000000289
Robert J Chilton, José Silva-Cardoso
This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes. Evidence derived from major randomized clinical trials demonstrates that steroidal MRAs reduce mortality in patients with heart failure and reduced ejection fraction. Initial positive findings observed in patients with chronic kidney disease and type 2 diabetes (T2D) indicate the possible mechanisms of action of nonsteroidal MRAs, and the clinical benefits for patients with cardiorenal disease and T2D. This article supports the application of basic science concepts to expand our understanding of the molecular mechanisms of action involved in pathophysiology. This approach encourages the development of treatment options before diseases clinically manifest. Video Abstract: http://links.lww.com/CAEN/A42.
{"title":"Mineralocorticoid receptor antagonists in cardiovascular translational biology.","authors":"Robert J Chilton, José Silva-Cardoso","doi":"10.1097/XCE.0000000000000289","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000289","url":null,"abstract":"<p><p>This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes. Evidence derived from major randomized clinical trials demonstrates that steroidal MRAs reduce mortality in patients with heart failure and reduced ejection fraction. Initial positive findings observed in patients with chronic kidney disease and type 2 diabetes (T2D) indicate the possible mechanisms of action of nonsteroidal MRAs, and the clinical benefits for patients with cardiorenal disease and T2D. This article supports the application of basic science concepts to expand our understanding of the molecular mechanisms of action involved in pathophysiology. This approach encourages the development of treatment options before diseases clinically manifest. Video Abstract: http://links.lww.com/CAEN/A42.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 3","pages":"e0289"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10056207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04eCollection Date: 2023-09-01DOI: 10.1097/XCE.0000000000000287
Desire Nzomessi, Emmanuelle Massie, Karim Gariani, Raphael Giraud, Philippe Meyer
SGLT2i are now recommended in a wide spectrum of indications including type 2 diabetes (T2DM), heart failure, and chronic kidney disease. This medication class is now available in combination with metformin, which is still a fundamental treatment in patients with T2DM. Despite excellent proven safety profile for both drugs, the expanding use of these agents in clinical practice may lead to an increased incidence of rare side effects, like metformin-associated lactic acidosis (MALA) and euglycemic diabetic ketoacidosis (EDKA), which can be life-threatening. A 58-year-old woman with T2DM and severe heart failure treated by metformin and empagliflozin developed progressive EDKA triggered by fasting that was also complicated by severe acute renal failure and MALA. She was successfully treated with intermittent hemodialysis. This case report highlights the importance of the recognition of rare, but very serious adverse effects due to combined metformin and SGLT2i therapy.
{"title":"Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.","authors":"Desire Nzomessi, Emmanuelle Massie, Karim Gariani, Raphael Giraud, Philippe Meyer","doi":"10.1097/XCE.0000000000000287","DOIUrl":"10.1097/XCE.0000000000000287","url":null,"abstract":"<p><p>SGLT2i are now recommended in a wide spectrum of indications including type 2 diabetes (T2DM), heart failure, and chronic kidney disease. This medication class is now available in combination with metformin, which is still a fundamental treatment in patients with T2DM. Despite excellent proven safety profile for both drugs, the expanding use of these agents in clinical practice may lead to an increased incidence of rare side effects, like metformin-associated lactic acidosis (MALA) and euglycemic diabetic ketoacidosis (EDKA), which can be life-threatening. A 58-year-old woman with T2DM and severe heart failure treated by metformin and empagliflozin developed progressive EDKA triggered by fasting that was also complicated by severe acute renal failure and MALA. She was successfully treated with intermittent hemodialysis. This case report highlights the importance of the recognition of rare, but very serious adverse effects due to combined metformin and SGLT2i therapy.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 3","pages":"e0287"},"PeriodicalIF":1.3,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9812492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}